We are pleased to share that our review article, “Expansion strategies for Vδ2 γδ T cells in cancer immunotherapy: Activation, cytokines, and culture conditions” has just been published in World Journal of Clinical Oncology.
In this review, we summarize and evaluate the latest strategies for expanding Vδ2 γδ T cells for cancer immunotherapy — covering different modes of activation, optimal cytokine combinations, and culture-condition that support GMP-compatible large-scale manufacturing.
We invite you to read the full article here
We are happy to share that the raw and processed RNA-seq data from our recent study on γδ T cells in chronic lymphocytic leukemia (CLL) are now publicly available in GEO. The dataset includes transcriptomic profiles of zoledronate-expanded Vδ2 γδ T cells and provides insights into their interaction with myeloid-derived suppressor cells (M-MDSCs) and the modulatory effect of vitamin C.
This resource complements our recent publication in Cancers and is intended to support further exploration of immune regulation and potential immunotherapeutic strategies in leukemia.
🔗 Access the dataset: GSE308261
📄 Read the paper: Cancers 2025
We are pleased to share our latest publication in BIOCELL, where we report that butyrophilin (BTN) genes—key regulators of γδ T cell activity—are significantly downregulated in chronic lymphocytic leukemia (CLL). Our analysis of public RNA-seq and microarray datasets reveals that reduced expression of BTN2A1, BTN3A1, BTN3A2, and BTN3A3 in CLL may impair γδ T cell-mediated immune responses.
Importantly, we found that lower BTN expression correlates with unmutated IGVH status, male sex, and poorer overall survival—highlighting the potential prognostic value of BTN profiling. These insights bring us closer to understanding γδ T cell exhaustion in CLL and open new avenues for biomarker development and immune-based therapies.
You can access the full article here.
We are proud to announce that Prof. Michal Zarobkiewicz has been appointed to the editorial boards of three esteemed international journals:
These appointments reflect Prof. Zarobkiewicz’s continued commitment to scientific excellence and his active role in shaping the future of biomedical research.
For more updates and insights, stay connected with our research at GammaDelta.
We are pleased to announce the publication of our latest research article, “Characterisation of Cytotoxicity-Related Receptors on γδ T Cells in Chronic Lymphocytic Leukaemia,” in the journal Cells. This study provides an in-depth analysis of the expression patterns of receptors associated with cytotoxicity on γδ T cells in patients with chronic lymphocytic leukaemia (CLL). The findings offer valuable insights into the potential role of γδ T cells in CLL progression and their implications for immunotherapeutic strategies.
For a comprehensive understanding of our research and its implications, we invite you to read the full article here.
This publication represents a significant advancement in our ongoing efforts to explore the immunological landscape of CLL and underscores our commitment to contributing to the development of innovative therapeutic approaches.
We are pleased to announce the publication of our latest research article in the journal Cancers, titled “γδ T Cells Are Significantly Impacted by CLL Burden but Only Mildly Influenced by M-MDSCs.”
In this study, we investigated the impact of chronic lymphocytic leukemia (CLL) on γδ T cells and hypothesized that monocytic myeloid-derived suppressor cells (M-MDSCs) might drive these changes. However, our in vitro experiments demonstrated that while γδ T cells are markedly influenced by the overall CLL burden, the direct impact of M-MDSCs is minimal and does not fully explain the observed alterations in γδ T cells in CLL patients.
These findings provide new insights into the tumor microenvironment of CLL and raise further questions about the mechanisms affecting γδ T cell function. The full article is available here.
We are delighted to share that Prof. Michał Zarobkiewicz, leader of the gammadelta.pl research team, and Dr. Natalia Lehman, MD, have been appointed as editors of a special issue in the journal BIOCELL. The special issue, titled “The Role of γδ T Cells and iNKT Cells in Cancer: Unraveling Molecular Mechanisms and Therapeutic Potential,” will focus on the latest research into the roles of these unconventional immune cells in cancer development and therapy.
This editorial role highlights Prof. Zarobkiewicz’s outstanding expertise in immuno-oncology and reinforces our team’s ongoing commitment to groundbreaking cancer research. We invite researchers to submit original studies and reviews, contributing to this impactful exploration of γδ T cells and iNKT cells in cancer. For more details, visit the special issue announcement here.
We have recently published a new article about γδ T cells in chronic lymphocytic leukaemia. For the full article please click here. We observed a dysregulation of CD155 – TIGIT/DNAM-1 pathway. While CD226 (DNAM-1) was decreased on γδ T, TIGIT had higher expression. At the same time, CD155, a ligand of both DNAM-1 and TIGIT, was significantly overexpressed by leukaemic cells. Altogether this suggests a possible usefulness of TIGIT inhibitors as future therapeutics in chronic lymphocytic leukaemia.
We are happy to announce a new grant! We have received a Ministry of Science and Education grant for a study on γδ T cells in diabetes mellitus.
